Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

NeoCircle: postoperative ctDNA detection was associated with relapse after neoadjuvant therapy for early breast cancer

In the NeoCircle analysis of 116 patients with stage I to III breast cancer presented at ASCO 2025, postoperative molecular residual disease detected with a tumor-informed structural-variant assay was associated with a shorter relapse-free interval (HR 45.5; 95% CI 13.0 to 159.8) and shorter overall survival (HR 15.3; 95% CI 4.5 to 52.9).

Journal of Clinical Oncology